HYUNDAI PHARMACEUTICAL CO., LTD
004310 | KO
Overview
Corporate Details
- ISIN(s):
- KR7004310009
- LEI:
- Country:
- South Korea
- Address:
- 충청남도 천안시 동남구 풍세면 잔다리길 55, 천안시
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-07-30 00:00 |
Regulatory Filings
투자판단관련주요경영사항
|
Korean | 9.0 KB | ||
| 2025-07-14 00:00 |
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
|
Korean | 14.8 KB | ||
| 2025-07-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.05)
|
Korean | 876.8 KB | ||
| 2025-04-29 00:00 |
Regulatory Filings
투자판단관련주요경영사항
|
Korean | 10.4 KB | ||
| 2025-04-28 00:00 |
Regulatory Filings
투자판단관련주요경영사항
|
Korean | 8.5 KB | ||
| 2025-04-14 00:00 |
Quarterly Report
분기보고서 (2025.02)
|
Korean | 827.4 KB | ||
| 2025-02-27 00:00 |
AGM Information
정기주주총회결과
|
Korean | 23.9 KB | ||
| 2025-02-27 00:00 |
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | 9.8 KB | ||
| 2025-02-19 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 11.9 KB | ||
| 2025-02-19 00:00 |
Audit Report / Information
[첨부추가]사업보고서 (2024.11)
|
Korean | 524.8 KB | ||
| 2025-02-12 00:00 |
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
|
Korean | 15.8 KB | ||
| 2025-02-12 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 10.9 KB | ||
| 2025-02-12 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 109.6 KB | ||
| 2025-02-12 00:00 |
Notice of Dividend Amount
현금ㆍ현물배당결정
|
Korean | 8.6 KB | ||
| 2025-02-12 00:00 |
Notice of Dividend Amount
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
|
Korean | 6.1 KB |
Automate Your Workflow. Get a real-time feed of all HYUNDAI PHARMACEUTICAL CO., LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for HYUNDAI PHARMACEUTICAL CO., LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for HYUNDAI PHARMACEUTICAL CO., LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops specialty medicines for the dermatology, urology, and otolaryngology clinical markets.
South Korea
067290
South Korea
067290
Develops plant-derived drugs for urinary system diseases, with a lead candidate in Phase III trials.
United States of America
MENS
United States of America
MENS
Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.
Japan
4556
Japan
4556
R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.
Japan
4521
Japan
4521
Developing stem cell-based biologics for rare and serious eye diseases.
United States of America
KALA
United States of America
KALA
Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.
United States of America
KLRS
United States of America
KLRS
Developing oral protease inhibitors for rare diseases like hereditary angioedema (HAE).
United States of America
KALV
United States of America
KALV
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel
KMDA
Israel
KMDA
Develops specialty plasma-derived therapeutics for rare and serious diseases.
United States of America
KMDA
United States of America
KMDA